Annovis Bio, Inc. (ANVS)

Annovis Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	14.22	19.53	10.55	5.75	28.38	45.69
Cash & Short-Term Investments	14.22	19.53	10.55	5.75	28.38	45.69
Cash Growth	-36.05%	85.11%	83.36%	-79.72%	-37.89%	465.79%
Other Current Assets	2.02	1.55	3.37	4.45	7.64	0.32
Total Current Assets	16.24	21.08	13.93	10.21	36.02	46
Total Assets	16.24	21.08	13.93	10.21	36.02	46
Accounts Payable	5.28	2.59	2.31	1.29	3.96	0.69
Accrued Expenses	7.51	1.04	1.58	2.99	3.74	0.82
Total Current Liabilities	12.79	3.64	3.88	4.28	7.7	1.51
Other Long-Term Liabilities	0.33	0.6	0.74	13.68	-	-
Total Long-Term Liabilities	0.33	0.6	0.74	13.68	-	-
Total Liabilities	13.12	4.23	4.62	17.96	7.7	1.51
Common Stock	0	0	0	0	0	0
Additional Paid-in Capital	184.43	180.55	144.16	102.51	82.38	73.22
Retained Earnings	-181.31	-163.7	-134.85	-110.26	-54.05	-28.73
Shareholders' Equity	3.13	16.85	9.31	-7.75	28.32	44.5
Total Liabilities & Equity	16.24	21.08	13.93	10.21	36.02	46
Net Cash (Debt)	14.22	19.53	10.55	5.75	28.38	45.69
Net Cash Growth	-27.20%	85.11%	83.36%	-79.72%	-37.89%	465.79%
Net Cash Per Share	0.61	0.95	0.86	0.64	3.48	5.99
Book Value	3.13	16.85	9.31	-7.75	28.32	44.5
Book Value Per Share	0.13	0.82	0.76	-0.86	3.47	5.83
Tangible Book Value	3.13	16.85	9.31	-7.75	28.32	44.5
Tangible Book Value Per Share	0.13	0.82	0.76	-0.86	3.47	5.83

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q